Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group

Blood (2012) 120 (21): 1452.

https://doi.org/10.1182/blood.V120.21.1452.1452

Published: 2012

Journal Articles

Clofarabine-Based Chemotherapy for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. the Spanish Experience

Pere Barba, Antonia Sampol, MD, María Calbacho, Jose Gonzalez, MD, Josefina Serrano, Pilar Martinez-Sanchez, MD, Pascual Fernandez, MD., Raimundo Garcia-Boyero, MD, Rodrigo Martino, MD, PhD, Pilar Delgado, MD, Jose Angel Hernandez-rivas, MD, Eloy Del Potro, MD, Soledad Gonzalez-Muñiz, MD, MAria Isabel Gomez-Sanchez, MD, Adolfo de la Fuente, MD, Javier Bueno, Josep-Maria Ribera, MD, PhD

Blood (2011) 118 (21): 4246.

https://doi.org/10.1182/blood.V118.21.4246.4246

Published: 2011

Journal Articles

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline-based regimens

Blood (2011) 117 (6): 1799–1805.

https://doi.org/10.1182/blood-2010-04-277434

Published: 2011

Journal Articles

Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.

Blood (2010) 116 (21): 1066.

https://doi.org/10.1182/blood.V116.21.1066.1066

Published: 2010

Journal Articles

Validation of the European Leukemia Net (ELN) Genetic Classification of Acute Myeloid Leukemia: Inclusion of Monosomal Karyotype Improves Prognostic Discrimination

Blood (2010) 116 (21): 1712.

https://doi.org/10.1182/blood.V116.21.1712.1712

Published: 2010

Journal Articles

Therapy-Related PML-RARα Leukemia: An Emerging Disease. Report of 10 Cases From One Department of Hematology.

Maida Navarrete, MD, Teresa Vallespi, MD, PhD, Anny Jaramillo, MD, Carmen Sánchez-Morata, MD, Carlos Palacio, MD, Noemí Martínez-Morgado, Ángel Guerra-Moreno, Margarita Ortega, PhD, Javier Bueno, MD

Blood (2009) 114 (22): 1016.

https://doi.org/10.1182/blood.V114.22.1016.1016

Published: 2009

Journal Articles

Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse.

Pau Montesinos, Jordi Esteve, Edo Vellenga, Concha Rivas, Salut Brunet, Montserrat Arnan, Jose D. Gonzalez, Pedro Sanchez, Joaquín Díaz-Mediavilla, Amparo Verdeguer, Lourdes Escoda, Elena Amutio, Vicente Rubio, Inmaculada Perez, Ramon Guardia, Javier Bueno, Bob Lowenberg, Miguel A. Sanz

Blood (2009) 114 (22): 1062.

https://doi.org/10.1182/blood.V114.22.1062.1062

Published: 2009

Journal Articles

A New Prognostic Scoring System Including Transfusion Dependency and Cytogenetic Abnormalities for Patients with Chronic Myelomonocytic Leukemia.

Blood (2009) 114 (22): 1750.

https://doi.org/10.1182/blood.V114.22.1750.1750

Published: 2009

Journal Articles

Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.

Blood (2009) 114 (22): 4711.

https://doi.org/10.1182/blood.V114.22.4711.4711

Published: 2009

Journal Articles

Global DNA Methylation Status of CD4+ T-Cell Population in Mielodysplastic Syndromes.

Angel Guerra-Moreno, Carlos Palacio, MD, Noemí Martínez-Morgado, Margarita Ortega, Maida Navarrete, M.D., Carmen Sánchez-Morata, M.D., Laura Gallur, MD, Javier Bueno, Teresa Vallespi, MD.PhD.

Blood (2009) 114 (22): 4424.

https://doi.org/10.1182/blood.V114.22.4424.4424

Published: 2009

Journal Articles

A Phase I/II, National, Multicenter, Open Label Study of Bortezomib (Velcade) and Fludarabine, Cytarabine and Idarubicin (Flag-Ida) (V-Flag-Ida) in Pts with Relapsed and/or Refractory Acute Myeloblastic Leukemia (AML).

Maria-Victoria Mateos, Rafael Martínez, Salut Brunet, Maria-Belén Vidriales, Albert Oriol, MD, Juan José Lahuerta, MD, PhD, Mari Luz Amigo, Jordi Esteve, Javier de la Rubia, Luis Palomera, Javier Bueno, Jesus F San Miguel

Blood (2009) 114 (22): 4140.

https://doi.org/10.1182/blood.V114.22.4140.4140

Published: 2009

Journal Articles

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial Including the Use of Propensity Score (PS) Method to Reduce Assignment Bias.

Blood (2009) 114 (22): 322.

https://doi.org/10.1182/blood.V114.22.322.322

Published: 2009

Journal Articles

Chronic Myelomonocytic Leukemia (CMML) with More Than 15% of Ring Sideroblasts in Bone Marrow: An Overlapping Disorder Between CMML and Refractory Anemia with Ring Sideroblasts.

Blood (2009) 114 (22): 290.

https://doi.org/10.1182/blood.V114.22.290.290

Published: 2009

Journal Articles

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial.

Blood (2008) 112 (11): 3291.

https://doi.org/10.1182/blood.V112.11.3291.3291

Published: 2008

Journal Articles

Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Results of the PETHEMA LPA2005 Trial Using All- Trans Retinoic Acid and Anthracycline with Cytarabine for High-Risk Patients

Miguel A. Sanz, MD, PhD, Pau Montesinos, Aleksandra Holowiecka, Gustavo Milone, Chelo Rayon, Elena de Lisa, Javier de la Serna, Salut Brunet, Angel Leon, Isabel Krsnik, Concha Rivas, Jose M. Ribera, Jose Gonzalez, Joaquín Díaz- Mediavilla, Javier Bueno, Jose David Gonzalez, Juan Bergua, Marcos Gonzalez

Blood (2008) 112 (11): 138.

https://doi.org/10.1182/blood.V112.11.138.138

Published: 2008

Journal Articles

Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome

Blood (2008) 112 (11): 640.

https://doi.org/10.1182/blood.V112.11.640.640

Published: 2008

Journal Articles

The Prognostic Significance of Complex Karyotype in Philadelphia Chromosome-Negative (Ph−) Acute Lymphoblastic Leukemia (ALL) in Adults Is Related with Risk Group.

Isabel Granada, MD, Juan-Manuel Sancho, MD, Albert Oriol, MD, Mireia Morgades, MD, Concepción Bethencourt, MD, Ricardo Parody, MD, Jesús-María Hernández-Rivas, PhD, Maria-José Moreno, MD, Eloy Del-Potro, MD, Mar Tormo, MD, Concepción Rivas, MD, Miguel-Angel Sanz, PhD, Carlos Grande, MD, Javier Bueno, MD, Eugenia Abella, MD, Juan-José Ortega, PhD, Josep-Maria Ribera, PhD

Blood (2007) 110 (11): 3501.

https://doi.org/10.1182/blood.V110.11.3501.3501

Published: 2007

Journal Articles

Double Syngeneic Transplantation in Plasma Cell Leukaemia.

Cristina Barrenetxea, Ph, Manuel Callis, Ph, Javier Bueno, Ph, Antonio Julia, Ph, Jose L. Diaz, Ph

Blood (2006) 108 (11): 5347.

https://doi.org/10.1182/blood.V108.11.5347.5347

Published: 2006

Journal Articles

Graft Versus Host Disease after Granulocyte Infusion.

Cristina Barrenetxea, Ph, Francisco J. Zuazu, Ph, Javier Bueno, Ph, Antonio Julia, Ph, Jose L. Diaz, Ph

Blood (2006) 108 (11): 5266.

https://doi.org/10.1182/blood.V108.11.5266.5266

Published: 2006

Journal Articles

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Classical Risk Factors and Minimal Residual Disease (MRD). Interim Results of the PETHEMA ALL-AR-03 Trial.

Blood (2006) 108 (11): 1872.

https://doi.org/10.1182/blood.V108.11.1872.1872

Published: 2006

NARROW

Prognostic Impact of the Levels of Expression of Cell Surface Proteins Commonly Expressed by Blasts and Hematopoietic Precursor Cells in De Novo AML Patients: A Report From the Spanish Cetlam Study Group

Clofarabine-Based Chemotherapy for Relapsed/Refractory Adult Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. the Spanish Experience

Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all- trans retinoic acid and anthracycline-based regimens

Treatment for Primary Acute Myeloid Leukemia: Results of Two Consecutive Trials From the Spanish CETLAM Group Showing Improvement with the Use of G-CSF Priming and Precise Risk-Adapted Therapy.

Validation of the European Leukemia Net (ELN) Genetic Classification of Acute Myeloid Leukemia: Inclusion of Monosomal Karyotype Improves Prognostic Discrimination

Therapy-Related PML-RARα Leukemia: An Emerging Disease. Report of 10 Cases From One Department of Hematology.

Salvage Therapy with Chemotherapy- or Arsenic Trioxide-Based Regimens for Acute Promyelocytic Leukemia in First Relapse.

A New Prognostic Scoring System Including Transfusion Dependency and Cytogenetic Abnormalities for Patients with Chronic Myelomonocytic Leukemia.

Impact of Cytogenetics and New Molecular Markers On the Achievement of Complete Remission in Patients with Primary Acute Myeloid Leukemia. On Behalf of CETLAM Cooperative Group. Spain.

Global DNA Methylation Status of CD4+ T-Cell Population in Mielodysplastic Syndromes.

A Phase I/II, National, Multicenter, Open Label Study of Bortezomib (Velcade) and Fludarabine, Cytarabine and Idarubicin (Flag-Ida) (V-Flag-Ida) in Pts with Relapsed and/or Refractory Acute Myeloblastic Leukemia (AML).

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial Including the Use of Propensity Score (PS) Method to Reduce Assignment Bias.

Chronic Myelomonocytic Leukemia (CMML) with More Than 15% of Ring Sideroblasts in Bone Marrow: An Overlapping Disorder Between CMML and Refractory Anemia with Ring Sideroblasts.

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Baseline Risk Factors and Minimal Residual Disease (MRD). Results of the PETHEMA ALL-AR-03 Trial.

Risk-Adapted Treatment of Acute Promyelocytic Leukemia: Results of the PETHEMA LPA2005 Trial Using All- Trans Retinoic Acid and Anthracycline with Cytarabine for High-Risk Patients

Independent Impact of Iron Overload and Transfusion Dependency on Survival and Leukemic Evolution in Patients with Myelodysplastic Syndrome

The Prognostic Significance of Complex Karyotype in Philadelphia Chromosome-Negative (Ph−) Acute Lymphoblastic Leukemia (ALL) in Adults Is Related with Risk Group.

Double Syngeneic Transplantation in Plasma Cell Leukaemia.

Graft Versus Host Disease after Granulocyte Infusion.

Treatment of High-Risk (HR) Philadelphia Chromosome-Negative (Ph-) Adult Acute Lymphoblastic Leukemia (ALL) According to Classical Risk Factors and Minimal Residual Disease (MRD). Interim Results of the PETHEMA ALL-AR-03 Trial.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only